FWFrances Wu

Frances Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Frances Wu has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Evangelos S. Gragoudas

    Ocular Melanoma Center, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114

    4 shared publications
  • Ivana K. Kim

    Division of Ocular Oncology (I.K.K., F.W.), Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA

    4 shared publications
  • Anne Marie Lane

    Ocular Melanoma Center, Retina Service, Massachusetts Eye and Ear and Harvard Medical School, Boston, MA, USA

    2 shared publications
  • Anne Marie Lane

    Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, United States, USA

    2 shared publications
  • Ivana K. Kim

    Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA

    2 shared publications
  • Megan S. Steinkerchner

    Ocular Melanoma Center, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114

    2 shared publications

Latest Publications

  • Open Access

    Genetic Profiles of Transformed Indeterminate Melanocytic Lesions Versus Immediately Treated T1a Choroidal Melanomas

    by Saba Samet, Anne Marie Lane, Kiley Lazarek, Frances Wu, Ivana Kim

    Background/Objective: To compare genetic profiles and metastatic outcomes of patients with initially observed indeterminate choroidal lesions (IL), to patients with small choroidal melanomas treated immediately. Methods: In this retrospective comparative cohort study, gene expression profiling (GEP) data of patients initially diagnosed with indeterminate choroidal lesions (IL) and treated with radiotherapy upon documented growth was compared to a control cohort of patients immediately treated for T1a choroidal melanoma (IT). Results: In the IL group 18 patients, and in the IT group 41 patients, were included. Groups were similar in age and tumor thickness at treatment (median 2.4mm IL vs 2.5mm IT, p = 0.34). The IL group had greater largest basal diameter (p = 0.02). No statistically significant difference was found in distribution of GEP, PRAME status, or presence and type of driver mutations. The proportion of class 2 tumors was 33% in the IL group vs. 24% in the IT group (p = 0.64). No difference in metastasis or mortality was observed (p = 1.0 and p = 0.66, respectively). Conclusion: Among comparable cohorts of transformed indeterminate lesions and small choroidal melanomas, no differences in genetic profiles and metastatic outcomes were identified. However, the proportion of class 2 tumors in early-stage melanoma remains substantial. These findings suggest that an observation period for indeterminate lesions does not appear to influence genetic profile or metastatic risk.

  • OUTCOMES OF PERSISTENT EXUDATIVE RETINAL DETACHMENTS AFTER PROTON BEAM IRRADIATION FOR CHOROIDAL MELANOMA

    by Megan S. Steinkerchner, Anne M. Lane, Evangelos S. Gragoudas, Ivana K. Md Kim, Frances Wu

    Purpose: To assess the outcomes of persistent large exudative retinal detachments (ERDs) after proton beam irradiation for choroidal melanoma. Methods: A retrospective study evaluated patients with a diagnosis of ERD in the setting of choroidal melanoma treated with proton beam irradiation at a single academic tertiary center. Inclusion criteria were the presence of an ERD for at least three clock hours at the time of melanoma diagnosis. Data collected included tumor features, management, and visual and anatomical outcomes. Results: The study comprised 50 eyes of 50 patients with a median age of 51.7 years (range 19.3–78.5 years) and a median follow-up of 35.1 months (range 6.6–247.9 months). Thirty-five patients were treated with conservative management, which included observation or intraocular steroids, and 15 patients underwent surgical management with pars plana vitrectomy, drainage of subretinal fluid, endolaser, and silicone oil placement for persistent ERD at a median duration of 7.5 months (range 1.3–117.6 months) after proton beam irradiation. The study found no difference in outcomes of final visual acuity, radiation retinopathy, neovascular glaucoma, and enucleation between conservative and surgical management. Refractory ERD was found to be a significant risk factor for the development of neovascular glaucoma. Conclusion: Choroidal melanoma with a large ERD can be successfully treated with conservative or surgical management after proton beam radiation therapy.


  • Visual Outcomes after Proton Therapy for Recurrent Uveal Melanoma

    by Megan S. Steinkerchner, Caleb D. Hartley, Anne M. Lane, Frances Wu, Evangelos S. Gragoudas, Ivana K. Kim


  • Outcomes after Proton Beam Irradiation in Patients with Choroidal Melanoma Eligible for Investigational AU-011 Treatment

    by Frances Wu, Anne Marie Lane, Alexei Trofimov, Helen A. Shih, Evangelos S. Gragoudas, Ivana K. Kim

    Introduction: Vision loss is common in patients treated with radiotherapy for uveal melanoma. With proton beam irradiation (PBI), the prescribed dose is delivered to the tumor with a sharp dose reduction outside the target volume. However, radiation complications are likely to develop when tumors are located near the optic nerve or fovea. Treatment with light-activated AU-011 (belzupacap sarotalocan), an investigational drug which specifically targets tumor cells, may avoid these complications. We evaluated outcomes in a historical group of patients who fit eligibility criteria for AU-011 therapy and were treated with PBI. Methods: A consecutive series of patients who received PBI for small choroidal melanoma at a single center between 1986 and 2016 were identified. Consistent with eligibility criteria in clinical trials of AU-011, patients were included when tumor dimensions did not exceed 2.5 mm in maximum thickness and 10.0 mm in largest basal diameter (LBD). Snellen visual acuities were converted to logMAR for analysis. Visual acuity outcomes were analyzed in patients with an initial acuity of logMAR 0.7 or better (equivalent to Snellen 20/100). Rates of visual acuity loss and mortality were calculated using the Kaplan-Meier method. Acuity loss by tumor location was compared using log-rank testing. Rates of tumor recurrence, neovascular glaucoma (NVG), and eye loss were also described. Results: Two hundred and 22 patients were included in the study. The median age was 60.7 years (range 21.3–94.8 years). Median tumor thickness was 2.0 mm (range 1.2–2.5 mm), and median LBD was 8.0 mm (range 4.0–10.0 mm). Median follow-up was 6.9 years (range 1.0–30.2 years). In 204 patients with a baseline logMAR visual acuity of 0.7 or better, the mean baseline acuity was 0.15 (equivalent to Snellen 20/25), which decreased to 0.52 (approximately Snellen 20/70) by 5 years after PBI. Visual outcomes were significantly worse for patients with tumors located within 3 mm of the optic disc and/or fovea. Tumor recurrence (1.4%), NVG (4.5%), and eye loss (2.7%) were uncommon. Discussion: Despite the advantageous dose distribution of protons, over half of patients with small choroidal melanomas located near the optic disc or fovea had a visual acuity equivalent to 20/80 or worse at 5 years after PBI. Treatment with AU-011 may allow better vision preservation in small tumors that carry a high risk of vision loss with radiotherapy.


  • Growth rate of indeterminate choroidal lesions prior to melanoma diagnosis

    by Frances Wu, Anne Marie Lane, Monica M. Oxenreiter, Evangelos S. Gragoudas, Ivana K. Kim

    Purpose Small choroidal melanocytic lesions have a low rate of metastasis and can be reasonably managed with surveillance until they demonstrate evidence of growth or clinical risk factors for melanoma. However, even choroidal nevi are not stationary, with many exhibiting slow growth over time. We sought to quantify the growth rates of indeterminate choroidal lesions that were initially observed prior to a clinical diagnosis of melanoma. Methods A single-center retrospective study was performed of patients diagnosed with choroidal melanoma based upon clinical characteristics who were initially followed for indeterminate lesions over at least 6 months. Subjects were included if they had a minimum of two B-scan ultrasound measurements prior to the visit at which melanoma was diagnosed. Demographic and tumor characteristics were collected from the medical record. Growth rates were calculated as the change in lesion thickness in mm per month and were recorded at 6-month intervals; ultrasound measurements less than 1 month apart were excluded. The characteristics of indeterminate lesions with faster versus slower growth rates prior to melanoma diagnosis were compared. Results Fifty-four patients met inclusion criteria. The mean age at melanoma diagnosis was 67.4 years, and 53.7% were female. Subjects had a median of four B-scan ultrasound measurements prior to melanoma diagnosis (range 2–19) and were followed for a median of 40.6 months (range 9.9–138.0 months). The mean lesion thickness was 1.4 mm (range 0.5–2.2 mm) at presentation, and increased to 2.3 mm (range 1.5–5.7 mm) at melanoma diagnosis. The mean growth rate did not exceed 0.021 mm/month (95% CI: 0.004–0.039; equivalent to 0.25 mm/year) for indeterminate lesions, but increased to 0.057 mm/month (95% CI: 0.043–0.071 mm/month; equivalent to 0.68 mm/year) at the time of melanoma diagnosis. Rapidly growing lesions had a greater tumor thickness and shorter duration of observation at the time of melanoma diagnosis. Conclusion For most indeterminate choroidal lesions eventually diagnosed as melanoma, the lesion thickness was relatively stable for a period of time, then rose significantly between the penultimate visit and the final visit. These findings confirm the recommendation for continued monitoring of suspicious choroidal lesions, as the growth rate may accelerate just prior to melanoma diagnosis. Lesions with a mean growth rate of up to 0.25 mm/year were observed, whereas lesions clinically determined to have transformed into melanoma demonstrated a mean growth rate of 0.68 mm/year. These values provide a baseline for future studies and potential therapies directed at stabilizing or reducing the growth of indeterminate choroidal lesions or small choroidal melanomas. Limitations of this study include its retrospective nature and reliance on clinical diagnostic criteria.


  • OUTCOMES OF RHEGMATOGENOUS RETINAL DETACHMENT REPAIR FOLLOWING INFECTIOUS ENDOPHTHALMITIS

    by Frances Wu, Leo A. Kim

    Purpose: To determine the incidence of and identify risk factors for redetachment in eyes that underwent rhegmatogenous retinal detachment (RRD) repair after infectious endophthalmitis. Methods: Retrospective chart review of patients who had RRD surgery following a diagnosis of endophthalmitis from 2008 to 2021 at a tertiary referral center. Demographic and clinical characteristics as well as operative details were collected. Subjects with prior RRD, trauma, keratoprosthesis, or less than 3 months of postoperative follow-up were excluded. Univariate logistic regression analyses were performed. Results: Thirty-four eyes of 34 patients were included. Most subjects were male with a mean age of 60.1 years. Exogenous (58.8%) was more common than endogenous (41.2%) sources of endophthalmitis. Seventeen of 34 eyes (50.0%) experienced redetachment. Significant risk factors were infection with virulent organisms, hypotony, and postoperative proliferative vitreoretinopathy. Initial management with vitreous tap or vitrectomy, exogenous versus endogenous source, and surgical procedure were not associated with recurrent RRD. At the final follow-up, 32 of 34 eyes (91.2%) were attached, although more than one third of these had silicone oil. Conclusion: Redetachment occurred in half of eyes that underwent surgical repair of RRD after endophthalmitis. Early vitrectomy, with or without prior vitreous tap, was not associated with a higher risk of redetachment and improved the likelihood of a positive culture result. Culture data can aid in risk stratification because organism virulence was a risk factor for recurrent RRD. Although visual outcomes were generally poor, most retinas remained attached at the final visit.


  • Acute Idiopathic Maculopathy Following SARS-CoV-2 Vaccination

    by Isaac D. Bleicher, Daniel Brill, Frances Wu, Lucia Sobrin, Nimesh Patel

    A 49-year-old man presented with acute unilateral blurred vision one week after SARS-CoV-2 vaccination. A unilateral serous detachment of the macula, intraretinal hemorrhages, vitritis, and anterior chamber cell was found. Diagnostic testing was negative for infectious and inflammatory causes, and a diagnosis of acute idiopathic maculopathy (AIM) was made. Symptoms and serous detachment resolved over 12 weeks, with residual retinal pigment epithelial changes consistent with the disease course. AIM is a rare diagnosis that presented in close proximity to SARS-CoV-2 vaccination without evidence of coxsackievirus infection. Further research is necessary to clarify an association between this vaccine and uveitis.


  • Treatment of Aggressive Retinal Astrocytic Hamartoma with Oral Mechanistic Target of Rapamycin Inhibition

    by Frances Wu, Mark P. McGarrey, Kennedy R. Geenen, Alison H. Skalet, Florian H. Guillot, Jenny L. Wilson, Ankoor S. Shah, Efren Gonzalez, Elizabeth A. Thiele, Ivana K. Kim, et al.


  • Bilateral anterior segment dysgenesis and peripheral avascular retina with tractional retinal detachment in an infant with multiple congenital anomalies-hypotony-seizures syndrome 3

    by Frances Wu, Paula C. Goldenberg, Shizuo Mukai

    Background: Multiple congenital anomalies-hypotony-seizures syndrome 3 (MCAHS3) is a rare autosomal recessive disorder caused by mutations in the PIGT gene. PIGT encodes phosphatidylinositol-glycan biosynthesis class T, which plays a crucial role in protein anchoring to cell membranes. The clinical presentation of MCAHS3 is variable in expression and severity, but can be characterized by developmental delay, seizures, hypotonia, facial dysmorphism, and other abnormalities. Materials and Methods: Case report. Results: We report unusual ocular findings including bilateral anterior segment dysgenesis, avascular retinal periphery, and tractional retinal detachment in a 1-month-old male infant with compound heterozygous PIGT mutations consistent with MCAHS3. Whole-exome sequencing did not detect any other genetic abnormalities. Conclusions: This case expands the clinical spectrum of MCAHS3 to include anomalies in ocular anterior segment and retinal vascular development. Given the rarity and the genetic heterogeneity of MCAHS3, giving rise to varied non-ocular phenotypes, it is possible that milder intraocular phenotypes could have gone unrecognized in the past.